<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Genetics and Molecular Medicine</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FBB774BA-F278-4C55-A986-487D8B64373A"><gtr:id>FBB774BA-F278-4C55-A986-487D8B64373A</gtr:id><gtr:firstName>Frederic</gtr:firstName><gtr:surname>Geissmann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2AD7BD9D-0149-4935-9C11-EB64C5B0EEB0"><gtr:id>2AD7BD9D-0149-4935-9C11-EB64C5B0EEB0</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Shaw</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C0420C4B-DBDD-43F0-BE83-0A439CE2A03B"><gtr:id>C0420C4B-DBDD-43F0-BE83-0A439CE2A03B</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Watt</gtr:surname><gtr:orcidId>0000-0001-9151-5154</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/893D66CD-2721-4DA1-BC08-7050127B4B3A"><gtr:id>893D66CD-2721-4DA1-BC08-7050127B4B3A</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:otherNames>H</gtr:otherNames><gtr:surname>Sacks</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8D61EDAA-70A5-4AC4-A5FF-A8A3448C0FD0"><gtr:id>8D61EDAA-70A5-4AC4-A5FF-A8A3448C0FD0</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Jonathan</gtr:otherNames><gtr:surname>Fairchild</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FB4046D3-FCA3-4BF4-90CA-1FA857B89F32"><gtr:id>FB4046D3-FCA3-4BF4-90CA-1FA857B89F32</gtr:id><gtr:firstName>Giovanna</gtr:firstName><gtr:surname>Lombardi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5C503690-5C36-4476-95EE-72D11F965BD6"><gtr:id>5C503690-5C36-4476-95EE-72D11F965BD6</gtr:id><gtr:firstName>Francesco</gtr:firstName><gtr:surname>Dazzi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6F03635D-C7E9-423B-8EA6-1A549DE2C298"><gtr:id>6F03635D-C7E9-423B-8EA6-1A549DE2C298</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:otherNames>Raihan</gtr:otherNames><gtr:surname>Ali</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1701F26B-544C-4E4A-ACF9-3E5F5AD90C8E"><gtr:id>1701F26B-544C-4E4A-ACF9-3E5F5AD90C8E</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>N</gtr:otherNames><gtr:surname>Newsome</gtr:surname><gtr:orcidId>0000-0001-6085-3652</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8757FBA7-07CE-4F4E-9510-AEBCDBE73724"><gtr:id>8757FBA7-07CE-4F4E-9510-AEBCDBE73724</gtr:id><gtr:firstName>Sian</gtr:firstName><gtr:otherNames>E</gtr:otherNames><gtr:surname>Harding</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/62ADFDCC-D255-40A8-A691-E25F1EF2813F"><gtr:id>62ADFDCC-D255-40A8-A691-E25F1EF2813F</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:surname>Powrie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL022699%2F1"><gtr:id>93E17F44-829F-45E3-B0E6-6C0C4A63F5E7</gtr:id><gtr:title>Overcoming immunological barriers to regenerative medicine</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L022699/1</gtr:grantReference><gtr:abstractText>The goal of the field of regenerative medicine is to replace damaged or diseased tissue and thereby find cures for diseases that are currently untreatable. At present two different approaches appear feasible: one is to stimulate the body's own cells to repair the tissue and the other is to transplant new cells into the body. In the case of cell transplantation one could transplant cells from one individual to another (allogeneic cells), as happens routinely in blood donation. Alternatively, one could isolate a small number of a patient's own skin or blood cells and convert them in the lab into cells called pluripotent stem cells that can then form any tissue in the body, so that patients can be treated with their own cells. 

No matter which strategy is taken, it is essential to overcome the body's natural immune defences in order for the treatment to succeed. In the case of allogeneic cells, the body recognises that the cells as foreign and kills them - the reason why this is not a problem in blood donation is that there are so many donors in the population that good matches for different individuals can be found. Even when the potential treatment involves the patient's own cells, the immune system can be provoked in response to tissue damage, resulting in inflammation whereby immune cells of the body respond to danger signals and engulf the transplanted cells.

We have assembled a team of researchers from different backgrounds to collaborate in order to find new ways to control the immune system to make regenerative medicine treatments more effective. Our team includes researchers with many years' experience in organ transplantation, who are developing ways of reducing the need for immunosuppressive drugs, and researchers who are already carrying out clinical trials of cell transplantation to cure certain forms of blindness and liver failure. We also have experts who are comparing whether cell transplantation or endogenous repair are better approaches for treating heart failure, experts in immunology, pluripotent stem cells and cells from adult tissues. 

We have set out to answer three questions that are of central importance in regenerative medicine. We want to identify the proteins that transplanted cells secrete to communicate with the immune system and discover whether different cell types produce different signals. It might be that liver cells produce different signals to eye cells, or that liver cells produce different signals if they have come from an adult rather than a pluripotent stem cell. This information will help us decide whether cells from one source might be better for transplantation than those from another source, and will also give us clues about the best ways to protect the cells from immune attack. The next question is whether the signals we identify as potentially contributing to transplant failure can be blocked, for example by coating cells with a protein that protects them from attack or by transplanting back immune cells generated from pluripotent stem cells. The final question is how inflammation contributes to endogenous repair and influences the fate of transplanted cells. We will identify different types of inflammatory cell and then examine whether destroying each cell type improves or worsens tissue repair.

Our research will lead eventually to improved treatments for blindness, heart failure, liver failure and inflammatory bowel disease. Our discoveries will be shared with other researchers, so that they can apply our observations, experimental skills and tools to other important diseases. We believe that collaborations amongst researchers with very different perspectives offer the best opportunity to harness the body's immune system to make treatments more effective.</gtr:abstractText><gtr:technicalSummary>The innate and adaptive immune system can present formidable obstacles to successful regenerative medicine applications. To identify and circumvent these obstacles, the co-applicants propose to form a UK Regenerative Medicine Platform (UKRMP) hub on immunomodulation. We will pool our collective clinical and laboratory-based expertise in stem cell biology, whole organ transplantation, cell therapy, endogenous tissue repair and innate and adaptive immunity to answer the following questions:

1. How do differentiated cells signal to the host innate and adaptive immune system?
2. How do transplanted cells provoke adaptive immune responses?
3. How does the inflammatory niche contribute to endogenous repair and influence the fate of transplanted cells?

Each question will be tackled in one work package. In work package 1 we will use in vitro assays to compare how differentiated human cells isolated from the relevant tissue or induced from iPS cells signal to the immune system under steady state and hypoxic conditions. In work package 2 key findings from work package 1 will be validated in vivo using humanised mice. The use of iPS cell-derived dendritic cells to modulate immune tolerance and enhance Treg therapy, alone or in combination with complement inhibitory peptides, will be explored as a means of improving the survival and function of transplanted cells. In work package 3 we will examine the contribution of recently discovered subsets of macrophages, fibroblasts and dendritic cells to the inflammatory niche in the context of cell transplantation, chronic inflammation and endogenous repair.

Each question will be approached in the context of the following long-term clinical deliverables: improved efficacy of photoreceptor cell therapy to treat blindness; improved repair of damaged heart and intestine; and improved survival and functionality of transplanted hepatocytes as an alternative to liver transplantation.</gtr:technicalSummary><gtr:potentialImpactText>WHO WILL BENEFIT FROM THIS RESEARCH?
The immediate academic beneficiaries include all investigators who participate in the immunomodulation hub, both as PIs and collaborators, and all investigators associated with the UK Regenerative Medicine Platform. The benefit will extend to the diverse stem cell biology, transplant, immunology and cancer research communities in the UK and internationally. Clinicians involved in organ transplantation and regenerative medicine therapies will also be beneficiaries. The commercial sector will benefit, including companies named in the application, companies who subsequently partner the hub and companies that are less directly associated with the area. Members of the lay public, both healthy individuals and patients, will benefit. UK government agencies, including politicians, the Technology Strategy Board (TSB), MRC and regulatory agencies, such as the MHRA, will benefit. The benefits will not be restricted to the UK but will have an impact globally.

HOW WILL THEY BENEFIT FROM THIS RESEARCH?
Academics will benefit by increased knowledge of how the immune system can be harnessed to improve regenerative medicine therapies, through obtaining data to facilitate further funding applications and publications, through career progression and, particularly in the case of the staff employed directly on the grant, training opportunities that enable them to pursue an independent research career or transfer to other employment sectors (timescale: 3-5 years).

Several of the PIs involved in this application are clinically active and have close associations with NIHR Biomedical Research Centres. Clinicians will benefit by obtaining new knowledge that leads to the design of new clinical trials (timescale: 3-8 years).

Patients will benefit by improved treatment for a variety of diseases that currently lack optimal treatments, including heart failure, inflammatory bowel disease, blindness, and liver failure (time scale: 5-15 years). Healthy individuals will benefit by improved quality of life in old age (timescale 10-15 years), increased understanding of research (timescale 3 years), increased willingness to participate in clinical trials (timescale 3-5 years), and by seeing the successful achievement of key goals within the charitable sector, such as the British Heart Foundation (timescale: 5-10 years).

The commercial sector will benefit by having new knowledge on which to develop new therapeutics, new possibilities for partnering with academics, facilitated by the TSB Cell Therapy Catapult, and by selling materials, such as kits and antibodies, to researchers funded by the hub (timescale: 1-10 years). 

The UK government (timescale: 1-15 years) will benefit by generation of intellectual property, leverage of ongoing MRC investment in the Centre for Transplantation, commercialisation of products arising from the research, reduced health care costs and by involvement in the work force of people who would otherwise be unable to work through ill health. The reduced burden to the National Health Service will allow resources to be channelled into other areas, such as acute care. The stature of the UK internationally will increase, because the research carried out by the hub will impact on the global field of regenerative medicine.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2422220</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Advice for applicants for Wellcome Trust Sir Henry Dale Fellowships http://elifesciences.org/elife-news/webinar-report-Sir-Henry-Dale</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>224BD240-789F-4232-89F8-34EA24E9DF22</gtr:id><gtr:impact>Advice to postdocs on obtaining a career development award.</gtr:impact><gtr:outcomeId>58b1c70c2c7a63.96488670</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://elifesciences.org/elife-news/webinar-report-Sir-Henry-Dale</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stem Cell Research: From Utopian Dream to Reality (2016) https://www.youtube.com/watch?v=JIqULf7xJ90&amp;feature=em-subs_digest</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3865550A-DA77-475B-8D6F-E58E94A199A7</gtr:id><gtr:impact>Exhibition and video as part of 'Utopia 2016' exhibition at Somerset House.</gtr:impact><gtr:outcomeId>58b1c791228599.58828016</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=JIqULf7xJ90&amp;feature=em-subs_digest</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E613EDEC-66A5-45DB-9461-1ABA4482121A</gtr:id><gtr:title>A high-content platform to characterise human induced pluripotent stem cell lines.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25df3abbb45d58d1f4f1b458a06c1eb7"><gtr:id>25df3abbb45d58d1f4f1b458a06c1eb7</gtr:id><gtr:otherNames>Leha A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn><gtr:outcomeId>56b65c171d4804.66704434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F048FE4E-C511-4279-99EA-0109A8C9D7EF</gtr:id><gtr:title>Galectin-6 is a novel skin anti-microbial peptide that is modulated by the skin barrier and microbiome.</gtr:title><gtr:parentPublicationTitle>Journal of dermatological science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7226e789eee098ab80917b08604b3fa2"><gtr:id>7226e789eee098ab80917b08604b3fa2</gtr:id><gtr:otherNames>Natsuga K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0923-1811</gtr:issn><gtr:outcomeId>58b1c3518a2f72.85529519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E220BCA-A12B-462A-95B3-1B55CD60B4F3</gtr:id><gtr:title>Reducing prostaglandin E2 production to raise cancer immunogenicity.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ae60822116985236a4f06a688ae5de4"><gtr:id>7ae60822116985236a4f06a688ae5de4</gtr:id><gtr:otherNames>Zelenay S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>58b44f6a1a4e45.99907643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F81DBB8D-66ED-4A2E-98A2-94416B842283</gtr:id><gtr:title>Immunology's Twinning Triangle</gtr:title><gtr:parentPublicationTitle>European Journal of Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c3d996af1538616a357faa1bd979304"><gtr:id>4c3d996af1538616a357faa1bd979304</gtr:id><gtr:otherNames>Silva-Santos B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>58b44f69ef2808.45703461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8414E7C0-5F09-4CE5-88CA-2E2ED2626613</gtr:id><gtr:title>Inhibition of ?-catenin signalling in dermal fibroblasts enhances hair follicle regeneration during wound healing.</gtr:title><gtr:parentPublicationTitle>Development (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d93296fd678c34b32c22b34a6e8b3a63"><gtr:id>d93296fd678c34b32c22b34a6e8b3a63</gtr:id><gtr:otherNames>Rognoni E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0950-1991</gtr:issn><gtr:outcomeId>585d3d7542d9d4.11522871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC6FE72D-434F-4789-AB93-660E28D1892B</gtr:id><gtr:title>T-bet is a key modulator of IL-23-driven pathogenic CD4(+) T cell responses in the intestine.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bb9087393698e862100990fefa91b4c"><gtr:id>2bb9087393698e862100990fefa91b4c</gtr:id><gtr:otherNames>Krausgruber T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58b44f6420e852.75393062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EF5E4DB-A957-4791-AE5C-7FFB6F77B39D</gtr:id><gtr:title>Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58b44f5e321b58.19302464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>292BEED6-3BEC-4610-8AE8-1CD4C229D5B1</gtr:id><gtr:title>Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84fcea8d3b0649ebc2a5600412a364bb"><gtr:id>84fcea8d3b0649ebc2a5600412a364bb</gtr:id><gtr:otherNames>Than NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>58b44f684eaf28.41122937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D059432-F172-4ED3-B4ED-B195052B220B</gtr:id><gtr:title>Macrophage Infiltration and Alternative Activation during Wound Healing Promote MEK1-Induced Skin Carcinogenesis.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beab8993983a7ef93f31a3a6b5b6cc75"><gtr:id>beab8993983a7ef93f31a3a6b5b6cc75</gtr:id><gtr:otherNames>Weber C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>56b65c16af1f44.49671063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B6F8941-718F-4FCA-B896-8520570EE933</gtr:id><gtr:title>Mesenchymal stromal cells and liver fibrosis: a complicated relationship.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8299b312ebf18c3ea456eda22641fd71"><gtr:id>8299b312ebf18c3ea456eda22641fd71</gtr:id><gtr:otherNames>Haldar D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>58b44f687498d1.60884351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0C51AAF-91D2-4EB4-926D-0AC340B7F58B</gtr:id><gtr:title>Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97cdb892bd28119895c5dee797659702"><gtr:id>97cdb892bd28119895c5dee797659702</gtr:id><gtr:otherNames>Galleu A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5a900907e20542.13877548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E86FFF4-EDD3-456A-B08F-C74CAA4BE5D0</gtr:id><gtr:title>The complement factor 5a receptor 1 has a pathogenic role in chronic inflammation and renal fibrosis in a murine model of chronic pyelonephritis.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d90eb469a207980b8ace0bd12b36"><gtr:id>56b2d90eb469a207980b8ace0bd12b36</gtr:id><gtr:otherNames>Choudhry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>58b44f65a1e3e8.31201403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F15DD6DF-A03A-470D-8290-0EB08E24A1E4</gtr:id><gtr:title>A pH- and ionic strength-dependent conformational change in the neck region regulates DNGR-1 function in dendritic cells.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c37b400902a70d7abb8dbfaf79347a6f"><gtr:id>c37b400902a70d7abb8dbfaf79347a6f</gtr:id><gtr:otherNames>Hanc P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>58b44f65770783.64084230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D085836-BD48-44FE-BB36-3B56DD984033</gtr:id><gtr:title>Pelota Regulates Epidermal Differentiation by Modulating BMP and PI3K/AKT Signaling&amp;nbsp;Pathways.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a510e68f28dfd260e7a95d6b6a3c09a"><gtr:id>1a510e68f28dfd260e7a95d6b6a3c09a</gtr:id><gtr:otherNames>Elkenani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>58b1c351da9c98.97380306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9B9D2CD-FC6A-4B36-A7BB-AA371C1316B9</gtr:id><gtr:title>Takotsubo Cardiomyopathy and Sepsis.</gtr:title><gtr:parentPublicationTitle>Angiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ff877b04830efd681902b5499b2c343"><gtr:id>1ff877b04830efd681902b5499b2c343</gtr:id><gtr:otherNames>Cappelletti S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-3197</gtr:issn><gtr:outcomeId>58b44f67788218.81814344</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76A09CEC-93D7-4823-A85B-308BEF4619E2</gtr:id><gtr:title>Treg therapy in transplantation: a general overview.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32ae8244d7b23002c2b8fee8ecc0bf07"><gtr:id>32ae8244d7b23002c2b8fee8ecc0bf07</gtr:id><gtr:otherNames>Romano M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>58b44f67cf3ae6.52957011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15D60305-4D6E-4BA5-8DA9-B199E82BE48B</gtr:id><gtr:title>Scalable topographies to support proliferation and Oct4 expression by human induced pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8435a969a9e5f799aeea285557bd08a6"><gtr:id>8435a969a9e5f799aeea285557bd08a6</gtr:id><gtr:otherNames>Reimer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56b65c167977e6.55075265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54AC7D06-DC02-41C5-8704-7F481F008A59</gtr:id><gtr:title>Role of the lectin complement pathway in kidney transplantation.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f41571013db636d13570fa10eaf335ba"><gtr:id>f41571013db636d13570fa10eaf335ba</gtr:id><gtr:otherNames>Farrar CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>58b44f6a3e21d1.99818439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>545B4979-B2A1-4343-A8D2-5D8E87EC8583</gtr:id><gtr:title>Well, I Wouldn't be Any Worse Off, Would I, Than I am Now? A Qualitative Study of Decision-Making, Hopes, and Realities of Adults With Type 1 Diabetes Undergoing Islet Cell Transplantation.</gtr:title><gtr:parentPublicationTitle>Transplantation direct</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/381c4c566843615406a256eac879134e"><gtr:id>381c4c566843615406a256eac879134e</gtr:id><gtr:otherNames>Speight J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2373-8731</gtr:issn><gtr:outcomeId>58b44f669c99f0.66342900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B7EF189-DCE3-4C10-8AFF-E99750FD49B4</gtr:id><gtr:title>Non-alcoholic fatty liver disease and liver transplantation.</gtr:title><gtr:parentPublicationTitle>Metabolism: clinical and experimental</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d22a467f149e99cf045b65f81fa0294"><gtr:id>7d22a467f149e99cf045b65f81fa0294</gtr:id><gtr:otherNames>Khan RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0026-0495</gtr:issn><gtr:outcomeId>58b44f6980a076.79796319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D7F85DC-A0E4-4C3D-9F57-839127C8389A</gtr:id><gtr:title>Rapid and Efficient Stable Gene Transfer to Mesenchymal Stromal Cells Using a Modified Foamy Virus Vector.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fdb407de380fe4d6dfda8cafaaa3024"><gtr:id>7fdb407de380fe4d6dfda8cafaaa3024</gtr:id><gtr:otherNames>Sweeney NP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>58b44f5cd80467.76809311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EBDA3AD-7DA6-4626-A085-CBDFCC48A701</gtr:id><gtr:title>AAV-mediated liver-directed gene therapy for Acute Intermittent Porphyria: It is safe but is it effective?</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdd09773dacc5c44a0b45d39e50b5b28"><gtr:id>cdd09773dacc5c44a0b45d39e50b5b28</gtr:id><gtr:otherNames>Brunetti-Pierri N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>58b44f68daf2d0.01380427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34654B52-DE7D-4408-8FC0-84382B2458BB</gtr:id><gtr:title>APT070 (mirococept), a membrane-localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2a65dd598c0cffda8550314e8f13a61"><gtr:id>a2a65dd598c0cffda8550314e8f13a61</gtr:id><gtr:otherNames>Xiao F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>58b44f60d8aef5.10628115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93D654C7-7CEE-4A61-90A6-E230C44B440C</gtr:id><gtr:title>Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a501a6a9751751d9907ecb97f8214a5f"><gtr:id>a501a6a9751751d9907ecb97f8214a5f</gtr:id><gtr:otherNames>Scott? C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>58b44f6180bf05.30562909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96B1181D-D829-4E63-8867-AB0F0211B63C</gtr:id><gtr:title>Galectin-1 is required for the regulatory function of B cells.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58ff17d77279e3959684be392b8509a3"><gtr:id>58ff17d77279e3959684be392b8509a3</gtr:id><gtr:otherNames>Alhabbab R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a90090830ceb6.68948624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE1188AE-99F1-4311-9E6A-8202A9B540F6</gtr:id><gtr:title>Reduced TCR Signaling Contributes to Impaired Th17 Responses in Tolerant Kidney Transplant Recipients.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a852e087195ad0146102a9de3e4ab8b"><gtr:id>4a852e087195ad0146102a9de3e4ab8b</gtr:id><gtr:otherNames>Nova-Lamperti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>5a900c1e093ab7.13421564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96691833-71FA-492D-A1DA-C43EA00A30D3</gtr:id><gtr:title>Systemic autoimmunity induced by the TLR7/8 agonist Resiquimod causes myocarditis and dilated cardiomyopathy in a new mouse model of autoimmune heart disease.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0a9e4cfa1532194c84e450166c01297"><gtr:id>d0a9e4cfa1532194c84e450166c01297</gtr:id><gtr:otherNames>Hasham MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>5a2fd6c4e619a6.10009179</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD6BE67A-A6F1-4A67-80BA-DE14506E513C</gtr:id><gtr:title>Inactivation of the type I interferon pathway reveals long double-stranded RNA-mediated RNA interference in mammalian cells.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/286b5566ea07c52c68c0c1853dbe8457"><gtr:id>286b5566ea07c52c68c0c1853dbe8457</gtr:id><gtr:otherNames>Maillard PV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>58b44f6517a9b7.07234613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7731EE33-68B9-44DD-9C74-CEA2C5B652E2</gtr:id><gtr:title>Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3d1f365e7f237e849abd7b8a60e266e"><gtr:id>d3d1f365e7f237e849abd7b8a60e266e</gtr:id><gtr:otherNames>Armstrong MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>58b44f6242de94.45986566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C5F7CA5-700D-4B7A-A13E-194979CE693D</gtr:id><gtr:title>Immune modulation by apoptotic dental pulp stem cells in vivo.</gtr:title><gtr:parentPublicationTitle>Immunotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80f402ed5a658810e9f8ef86605e10f1"><gtr:id>80f402ed5a658810e9f8ef86605e10f1</gtr:id><gtr:otherNames>Laing AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1750-743X</gtr:issn><gtr:outcomeId>5a900908620382.32034888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2195BED7-9FE7-4DD0-BBB4-E0C5A6C2A5F0</gtr:id><gtr:title>Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T&amp;nbsp;cells.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ced27b6e13cce3be4ebc210a5de603bd"><gtr:id>ced27b6e13cce3be4ebc210a5de603bd</gtr:id><gtr:otherNames>Chen HH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58b44f63ed5c67.05041571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB11ABDE-35C6-4BDB-A3B0-18C72A9068FE</gtr:id><gtr:title>Mentoring perception, scientific collaboration and research performance: is there a 'gender gap' in academic medicine? An Academic Health Science Centre perspective.</gtr:title><gtr:parentPublicationTitle>Postgraduate medical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76a1945522504b4fb8a393c014f7cd10"><gtr:id>76a1945522504b4fb8a393c014f7cd10</gtr:id><gtr:otherNames>Athanasiou T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0032-5473</gtr:issn><gtr:outcomeId>58b44f674401d4.85737808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A51F4268-8932-42D4-97AC-BF5E4E7EEC52</gtr:id><gtr:title>Flow cytometric analysis of inflammatory and resident myeloid populations in mouse ocular inflammatory models.</gtr:title><gtr:parentPublicationTitle>Experimental eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e451f25e48390bcafc37ac57e554706"><gtr:id>2e451f25e48390bcafc37ac57e554706</gtr:id><gtr:otherNames>Liyanage SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-4835</gtr:issn><gtr:outcomeId>58b44f5a79ee04.86166443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F202E7F8-0155-41EE-A973-36D7E96A8063</gtr:id><gtr:title>Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7db1b373f7864413af24edeb44e89bed"><gtr:id>7db1b373f7864413af24edeb44e89bed</gtr:id><gtr:otherNames>Schwerd T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>58b44f646f2428.43335307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B32101A4-9C05-4870-A0CD-5FF4AD5E9D6D</gtr:id><gtr:title>IL-10-produced by human transitional B-cells down-regulates CD86 expression on B-cells leading to inhibition of CD4+T-cell responses.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a852e087195ad0146102a9de3e4ab8b"><gtr:id>4a852e087195ad0146102a9de3e4ab8b</gtr:id><gtr:otherNames>Nova-Lamperti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58b44f611d81f1.84314798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5E2D563-3A2E-4C3D-A953-88B5C84249AF</gtr:id><gtr:title>Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2692eb3791498ab9cd158794f5130561"><gtr:id>2692eb3791498ab9cd158794f5130561</gtr:id><gtr:otherNames>Georgiadis A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>58b44f5a503459.91174967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B93E566C-B822-4301-9C99-4F746ABC976C</gtr:id><gtr:title>Murine Models of Acute Alcoholic Hepatitis and Their Relevance to Human Disease.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28154d7af1e6fe929fe840bbef07537c"><gtr:id>28154d7af1e6fe929fe840bbef07537c</gtr:id><gtr:otherNames>Wilkin RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>58b44f69bed2c8.88133117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5410C5D2-3F4C-4E10-AC32-792127379ECA</gtr:id><gtr:title>Concise Review: Pluripotent Stem Cell-Derived Cardiac Cells, A Promising Cell Source for Therapy of Heart Failure: Where Do We Stand?</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdaafd6c6982f21324856ab367eeb82a"><gtr:id>fdaafd6c6982f21324856ab367eeb82a</gtr:id><gtr:otherNames>Gouadon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>58b44f67a49ce1.87704882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E16C1872-D6C3-4736-BB8E-8912C6B38737</gtr:id><gtr:title>Integrative Phosphoproteomics Links IL-23R Signaling with Metabolic Adaptation in Lymphocytes.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eeb6759937032a8d8bba7bb7dc7c4996"><gtr:id>eeb6759937032a8d8bba7bb7dc7c4996</gtr:id><gtr:otherNames>Lochmatter C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58b44f64458788.12093319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3029D4B-D33A-45B4-A7EC-1BB8C5FC9E63</gtr:id><gtr:title>Donor and host photoreceptors engage in material transfer following transplantation of post-mitotic photoreceptor precursors.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00ccfd6d705dd27d9f8e807d299400ce"><gtr:id>00ccfd6d705dd27d9f8e807d299400ce</gtr:id><gtr:otherNames>Pearson RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58b44f5a25ab09.67432713</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3B82FC7-2CC9-42CF-98AE-57999E657228</gtr:id><gtr:title>Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f41571013db636d13570fa10eaf335ba"><gtr:id>f41571013db636d13570fa10eaf335ba</gtr:id><gtr:otherNames>Farrar CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>58b44f660d3d87.88616234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D754F032-C7A9-434E-8575-E59CFB15F649</gtr:id><gtr:title>Multimodal analysis of ocular inflammation using the endotoxin-induced uveitis mouse model.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/223de347f407a52493f71e53c17bc658"><gtr:id>223de347f407a52493f71e53c17bc658</gtr:id><gtr:otherNames>Chu CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>58b44f5af33c10.59717042</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B08A5FF0-1581-471B-9AD4-678AA92D6536</gtr:id><gtr:title>Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c23c308038779d6077fc6d042aea6ae"><gtr:id>5c23c308038779d6077fc6d042aea6ae</gtr:id><gtr:otherNames>Hassan HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>58b44f5d8d6ba3.00604599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1DA77CD-C930-4838-8D8C-33E58811BBCE</gtr:id><gtr:title>Liver regeneration - mechanisms and models to clinical application.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0cc27e8940b9a686367e1aaa8e2fec9"><gtr:id>c0cc27e8940b9a686367e1aaa8e2fec9</gtr:id><gtr:otherNames>Forbes SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-5045</gtr:issn><gtr:outcomeId>58b44f690da1d6.14673392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A118F73-D294-4B32-B0D2-206BF44B2CD1</gtr:id><gtr:title>ROR?t inhibitors suppress T(H)17 responses in inflammatory arthritis and inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb9335a7424590f33f2bb07ab9e8240e"><gtr:id>fb9335a7424590f33f2bb07ab9e8240e</gtr:id><gtr:otherNames>de Wit J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58b44f64946d56.05908130</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9760A572-FA7D-4CF1-A18F-3876DF6A28E9</gtr:id><gtr:title>Defining the microbial transcriptional response to colitis through integrated host and microbiome profiling.</gtr:title><gtr:parentPublicationTitle>The ISME journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f65e131ab5969bf415962c6e650b8411"><gtr:id>f65e131ab5969bf415962c6e650b8411</gtr:id><gtr:otherNames>Ilott NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1751-7362</gtr:issn><gtr:outcomeId>58b44f62ba7d31.11516064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98854F8F-690C-4A3E-8C2F-4D241758B66A</gtr:id><gtr:title>CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67e000b9b63dbeb08f7036e69e9d1799"><gtr:id>67e000b9b63dbeb08f7036e69e9d1799</gtr:id><gtr:otherNames>Wilhelm A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>58b44f62105104.23620719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F308531E-9A4B-4C62-8CF4-816916B23F57</gtr:id><gtr:title>Fibroblast heterogeneity: implications for human disease.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcf85181d460d7697454708928c59a0c"><gtr:id>fcf85181d460d7697454708928c59a0c</gtr:id><gtr:otherNames>Lynch MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>5a91ca0233ac92.69873510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5954D9B0-BD5B-47DA-B0DF-A5105CB0B7ED</gtr:id><gtr:title>Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/106c16d6f9893f7a7d87dd13518ba4f7"><gtr:id>106c16d6f9893f7a7d87dd13518ba4f7</gtr:id><gtr:otherNames>Canavan JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>58b44f5e002831.52845760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>170A1CC8-20F9-43CC-BFF8-B605F4614B42</gtr:id><gtr:title>Compartmentalized Epidermal Activation of ?-Catenin Differentially Affects Lineage Reprogramming and Underlies Tumor Heterogeneity.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f73202f40da6be279f4cee11c98df47"><gtr:id>7f73202f40da6be279f4cee11c98df47</gtr:id><gtr:otherNames>Kretzschmar K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d6a4aa3e679.19148671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D16FB471-96D6-4DDD-BE9E-F46D57698220</gtr:id><gtr:title>Dimethylarginine dimethylaminohydrolase-2 deficiency promotes vascular regeneration and attenuates pathological angiogenesis.</gtr:title><gtr:parentPublicationTitle>Experimental eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5149d219d7240db05041302902c6636"><gtr:id>b5149d219d7240db05041302902c6636</gtr:id><gtr:otherNames>Lange C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-4835</gtr:issn><gtr:outcomeId>58b44f5ac62066.96831244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCEFB16D-5A67-41AA-99FB-3393E7D2448E</gtr:id><gtr:title>Integrative genomic and functional analysis of human oral squamous cell carcinoma cell lines reveals synergistic effects of FAT1 and CASP8 inactivation.</gtr:title><gtr:parentPublicationTitle>Cancer letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f41cbe1b43c0ac7c8d64667b5b475fb0"><gtr:id>f41cbe1b43c0ac7c8d64667b5b475fb0</gtr:id><gtr:otherNames>Hayes TF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0304-3835</gtr:issn><gtr:outcomeId>585d33a6370957.30769826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA4607C4-5BFA-4BA1-898E-D459868D5693</gtr:id><gtr:title>Increased CD40 Ligation and Reduced BCR Signalling Leads to Higher IL-10 Production in B Cells From Tolerant Kidney Transplant Patients.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a852e087195ad0146102a9de3e4ab8b"><gtr:id>4a852e087195ad0146102a9de3e4ab8b</gtr:id><gtr:otherNames>Nova-Lamperti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>58b44f5dd18de1.53181179</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38BE445D-5F59-4FE2-9D43-B3423A8DEF73</gtr:id><gtr:title>Cell Therapy for Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Trials.</gtr:title><gtr:parentPublicationTitle>Angiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88c13ec3c5baf54fcd395987713bc792"><gtr:id>88c13ec3c5baf54fcd395987713bc792</gtr:id><gtr:otherNames>Liew A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-3197</gtr:issn><gtr:outcomeId>58b44f66c0e761.01177275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FF6BB52-49EA-42B1-98CF-BA7B071C8D08</gtr:id><gtr:title>Induced Pluripotent Stem Cell Therapies for Degenerative Disease of the Outer Retina: Disease Modeling and Cell Replacement.</gtr:title><gtr:parentPublicationTitle>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/864644aa5b12b4d031b0305f549d041b"><gtr:id>864644aa5b12b4d031b0305f549d041b</gtr:id><gtr:otherNames>Di Foggia V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1080-7683</gtr:issn><gtr:outcomeId>58b44f66edefc8.04992732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77B40B12-CD1C-4132-BA49-4B7111AAB7C8</gtr:id><gtr:title>Clinical effectiveness of cell therapies in patients with chronic liver disease and acute-on-chronic liver failure: a systematic review protocol.</gtr:title><gtr:parentPublicationTitle>Systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84fcea8d3b0649ebc2a5600412a364bb"><gtr:id>84fcea8d3b0649ebc2a5600412a364bb</gtr:id><gtr:otherNames>Than NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2046-4053</gtr:issn><gtr:outcomeId>58b44f69354a64.90630847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A0E8848-DDF6-418A-A0F6-777ED0A23363</gtr:id><gtr:title>High speed sCMOS-based oblique plane microscopy applied to the study of calcium dynamics in cardiac myocytes.</gtr:title><gtr:parentPublicationTitle>Journal of biophotonics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afa428fa986d1aed22307bf44eb7d516"><gtr:id>afa428fa986d1aed22307bf44eb7d516</gtr:id><gtr:otherNames>Sikkel MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1864-063X</gtr:issn><gtr:outcomeId>58b44f5d5e7df6.01548410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C480BE69-4704-422F-BC15-A3A9289AF1ED</gtr:id><gtr:title>What Is Direct Allorecognition?</gtr:title><gtr:parentPublicationTitle>Current transplantation reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7a487776927702f0e2714d73f629af4"><gtr:id>c7a487776927702f0e2714d73f629af4</gtr:id><gtr:otherNames>Boardman DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b44f67f0e3d3.63133884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F18800E-A1AD-46BF-BF3B-9077F9F2640C</gtr:id><gtr:title>Systematic assessment of the influence of complement gene polymorphisms on kidney transplant outcome.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ad81811cead7fc395938bf1797e0921"><gtr:id>9ad81811cead7fc395938bf1797e0921</gtr:id><gtr:otherNames>Ermini L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>58b44f65c6b2f1.44507682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD087B15-5F0C-4193-94E1-AFA616C4C801</gtr:id><gtr:title>Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3d1f365e7f237e849abd7b8a60e266e"><gtr:id>d3d1f365e7f237e849abd7b8a60e266e</gtr:id><gtr:otherNames>Armstrong MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58b44f6261f677.11907158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6A2E611-9FF4-4AC9-BF60-1F50E95FC794</gtr:id><gtr:title>Actin is an evolutionarily-conserved damage-associated molecular pattern that signals tissue injury in.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08794cb11bb6465288c43686316208e2"><gtr:id>08794cb11bb6465288c43686316208e2</gtr:id><gtr:otherNames>Srinivasan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>58b44f654e0f37.16894888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E934DFAA-02D8-424D-BBD3-89FF87047536</gtr:id><gtr:title>Serum alkaline phosphatase in multidrug resistance 2 (Mdr2(-/-) ) knockout mice is strain specific.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15e68c617b011357137d3bb9f8bef859"><gtr:id>15e68c617b011357137d3bb9f8bef859</gtr:id><gtr:otherNames>Trivedi PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>58b44f62880fb1.39374851</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E912EEBD-ECDB-47EA-A306-7BE0E28431FD</gtr:id><gtr:title>Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7a487776927702f0e2714d73f629af4"><gtr:id>c7a487776927702f0e2714d73f629af4</gtr:id><gtr:otherNames>Boardman DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>58b1c351315b33.20278431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D80E7B5-D496-41F4-89E9-21D93ECC856D</gtr:id><gtr:title>New metrics for the Lancet Standing Commission on Liver Disease in the UK.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6682b85c220c8c8bd534e7066c4856a9"><gtr:id>6682b85c220c8c8bd534e7066c4856a9</gtr:id><gtr:otherNames>Williams R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58b44f6825ef12.34285601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3784AF5D-671F-467A-BC7B-E52778D41D70</gtr:id><gtr:title>Complement C3 Exacerbates Imiquimod-Induced Skin Inflammation and&amp;nbsp;Psoriasiform Dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f0af29501f6f53cfd7f9103c070c37b"><gtr:id>5f0af29501f6f53cfd7f9103c070c37b</gtr:id><gtr:otherNames>Giacomassi C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>58b44f5bb6a9a1.56157652</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07DF7E2B-67C1-44D1-AB3F-6F03DD3D680D</gtr:id><gtr:title>Entering the GOLDEN Age for Therapies in NASH.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4caa5dab30f9e88abea677496220ba2c"><gtr:id>4caa5dab30f9e88abea677496220ba2c</gtr:id><gtr:otherNames>Newsome PN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>58b44f69595bd7.84047622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>562A9D42-A09D-4ADE-A1EF-4B20DBD69347</gtr:id><gtr:title>Carbohydrate Counting at Meal Time Followed by a Small Secondary Postprandial Bolus Injection at 3 Hours Prevents Late Hyperglycemia, Without Hypoglycemia, After a High-Carbohydrate, High-Fat Meal in Type 1 Diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0c3d1341171b9f09a41fbff541803cb"><gtr:id>c0c3d1341171b9f09a41fbff541803cb</gtr:id><gtr:otherNames>Campbell MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>58b44f6653f463.97543317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>612F2927-7726-4A66-ACA7-AA0EDCFEBB18</gtr:id><gtr:title>The adaptive immune response to cardiac injury-the true roadblock to effective regenerative therapies?</gtr:title><gtr:parentPublicationTitle>NPJ Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5eecbd4c5c4510b4053e8608846e63b8"><gtr:id>5eecbd4c5c4510b4053e8608846e63b8</gtr:id><gtr:otherNames>Sattler S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2057-3995</gtr:issn><gtr:outcomeId>5a91d1f51034f1.52510813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2547E5E1-35FE-4782-93CC-05A0C9F078DA</gtr:id><gtr:title>Myeloid-Derived Vascular Endothelial Growth Factor and Hypoxia-Inducible Factor Are Dispensable for Ocular Neovascularization--Brief Report.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e451f25e48390bcafc37ac57e554706"><gtr:id>2e451f25e48390bcafc37ac57e554706</gtr:id><gtr:otherNames>Liyanage SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>58b44f5b8ec870.89468296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBD03D8F-3E23-4B84-B6C1-72100711313A</gtr:id><gtr:title>Human aplastic anaemia-derived mesenchymal stromal cells form functional haematopoietic stem cell niche in vivo.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10f607091bf48e37080efa9474227af7"><gtr:id>10f607091bf48e37080efa9474227af7</gtr:id><gtr:otherNames>Michelozzi IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>58b44f5cac32d9.62188809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10EA061A-A47A-4407-964D-DC646B8A5EE4</gtr:id><gtr:title>Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3d1f365e7f237e849abd7b8a60e266e"><gtr:id>d3d1f365e7f237e849abd7b8a60e266e</gtr:id><gtr:otherNames>Armstrong MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>58b44f61ab8933.46364586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C02A833-E6E8-4061-AC6D-E799BA3A272D</gtr:id><gtr:title>Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaba98b559e943cdb7dea20ac36b2e36"><gtr:id>aaba98b559e943cdb7dea20ac36b2e36</gtr:id><gtr:otherNames>D'Avola D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a36039f2fd247.65470569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>142590C3-6557-43EB-AC89-FDF86FFB6CA6</gtr:id><gtr:title>Regulatory T cells: tolerance induction in solid organ transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e40ea6a39fae2baf5393f722dd9d371"><gtr:id>3e40ea6a39fae2baf5393f722dd9d371</gtr:id><gtr:otherNames>Vaikunthanathan T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>5a900e327cb702.40512567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66C8768A-0E1F-46C6-91E6-49D5C2B444E8</gtr:id><gtr:title>Low-Blood Glucose Avoidance Training Improves Glycemic Variability in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: HypoCOMPaSS Trial.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5616411cd7328ea4c5c188760a95b781"><gtr:id>5616411cd7328ea4c5c188760a95b781</gtr:id><gtr:otherNames>Tan HK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>58b44f667b15e4.64416003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B4169D9-7363-469B-BB3B-1DF6D82E675E</gtr:id><gtr:title>Epidermal ?-catenin activation remodels the dermis via paracrine signalling to distinct fibroblast lineages.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7f3c7c9b639afee5a3567d0add97935"><gtr:id>b7f3c7c9b639afee5a3567d0add97935</gtr:id><gtr:otherNames>Lichtenberger BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56b65c15d7e944.24342557</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51138473-822B-4E67-8CC3-81F3DA11649C</gtr:id><gtr:title>Enhanced Ccl2-Ccr2 signaling drives more severe choroidal neovascularization with aging.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c340fcc0e6654cf4ac06274da7dbab7"><gtr:id>3c340fcc0e6654cf4ac06274da7dbab7</gtr:id><gtr:otherNames>Robbie SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>58b44f5b64f480.10563616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2086791D-E89D-4690-9CF4-E38AD7F7E207</gtr:id><gtr:title>Investigation of SLA4A3 as a candidate gene for human retinal disease.</gtr:title><gtr:parentPublicationTitle>Journal of negative results in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74b480ff7fb597230029eb8978ef4663"><gtr:id>74b480ff7fb597230029eb8978ef4663</gtr:id><gtr:otherNames>Downs LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1477-5751</gtr:issn><gtr:outcomeId>58b44f5b2a1791.53893354</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06000CCA-4E9D-45E0-AAD3-BE8279ED2022</gtr:id><gtr:title>Increased Bacterial Load and Expression of Antimicrobial Peptides in Skin of Barrier-Deficient Mice with Reduced Cancer Susceptibility.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7226e789eee098ab80917b08604b3fa2"><gtr:id>7226e789eee098ab80917b08604b3fa2</gtr:id><gtr:otherNames>Natsuga K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>56b65c164d6196.77257014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FEE096B-256C-4DD7-A793-D10528A1051E</gtr:id><gtr:title>Steatosis and liver stiffness measurements using transient elastography.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/959ea5d66d4532834a65d59f4c528246"><gtr:id>959ea5d66d4532834a65d59f4c528246</gtr:id><gtr:otherNames>Eddowes P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>58b44f61d8be58.30383533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEF55CC0-2DC9-45F1-BBC3-0142F3CDEAB2</gtr:id><gtr:title>Labeling of cell therapies: How can we get it right?</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d28dabb099cbcd327d02fdf83f74a111"><gtr:id>d28dabb099cbcd327d02fdf83f74a111</gtr:id><gtr:otherNames>Waiczies S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>5a900e32dca125.40885535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17CAE0C9-A52F-489A-9675-574205EFDDC1</gtr:id><gtr:title>Beneath the sword of Damocles: regenerative medicine and the shadow of immunogenicity.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9aabd38d22ef90645151cece851cdb1b"><gtr:id>9aabd38d22ef90645151cece851cdb1b</gtr:id><gtr:otherNames>Fairchild PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>58b44f67240e11.39360744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21D7A956-76E8-45D6-B472-2074EF4D30F1</gtr:id><gtr:title>Type 2 Diabetes: The Pathologic Basis of Reversible ?-Cell Dysfunction.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d0b748c440ff6afb9ac19f130df3198"><gtr:id>3d0b748c440ff6afb9ac19f130df3198</gtr:id><gtr:otherNames>White MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>58b44f6a780eb2.49476325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CC704BA-B5A2-45CA-8247-615110155338</gtr:id><gtr:title>CIRM and UKRMP: Different Ways to Invest in Regenerative Medicine.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27ad1f9d672510fc00f7ce023edcf45d"><gtr:id>27ad1f9d672510fc00f7ce023edcf45d</gtr:id><gtr:otherNames>Weissman IL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn><gtr:outcomeId>58b1c351b355c4.71202233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7E22AD6-65D4-4735-B795-8902DDA3B7A2</gtr:id><gtr:title>International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.</gtr:title><gtr:parentPublicationTitle>Cytotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc486506fecc65e007e03cd56f2f325c"><gtr:id>bc486506fecc65e007e03cd56f2f325c</gtr:id><gtr:otherNames>Galipeau J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1465-3249</gtr:issn><gtr:outcomeId>58b44f5d0c5023.97418973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD70338B-94B7-4B1F-8CB6-CC13762A2100</gtr:id><gtr:title>Non-alcoholic fatty liver disease in 2016.</gtr:title><gtr:parentPublicationTitle>British medical bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66a188508b7ccb440a303317a0b844c3"><gtr:id>66a188508b7ccb440a303317a0b844c3</gtr:id><gtr:otherNames>Townsend SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1420</gtr:issn><gtr:outcomeId>58b44f68aa58b1.87262362</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>148E6CE7-3F43-4642-81B9-DF84759D0263</gtr:id><gtr:title>ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e95616359167b66f43319565f0561f05"><gtr:id>e95616359167b66f43319565f0561f05</gtr:id><gtr:otherNames>Pearson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>58b44f64cfd717.46139010</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L022699/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>